ARMISTICE CAPITAL, LLC Acquires New Stake in TC BioPharm Holdin - GuruFocus.com
| TCBPW Stock | USD 0.02 0 15.00% |
Slightly above 57% of all TC BioPharm's sophisticated investors are looking to take a long position. The analysis of the overall investor sentiment regarding TC BioPharm plc suggests that some traders are interested. TC BioPharm's investing sentiment can be driven by a variety of factors including economic data, TC BioPharm's earnings reports, geopolitical events, and overall market trends.
TCBPW |
ARMISTICE CAPITAL, LLC Acquires New Stake in TC BioPharm Holdin GuruFocus.com
Read at news.google.com
 |
TC BioPharm Fundamental Analysis
We analyze TC BioPharm's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of TC BioPharm using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of TC BioPharm based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Retained Earnings
Retained Earnings Comparative Analysis
TC BioPharm is currently under evaluation in retained earnings category among its peers. Retained Earnings is a balance sheet account that refers to the portion of company income that is retained by the firm. In other words, it is a part of earnings that is not paid out as dividends or otherwise distributed to owners. Retained Earnings are calculated by adding net income to last period retained earnings and subtracting any dividends paid to owners.
TC BioPharm plc Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with TC BioPharm stock to make a market-neutral strategy. Peer analysis of TC BioPharm could also be used in its relative valuation, which is a method of valuing TC BioPharm by comparing valuation metrics with similar companies.
Peers
TC BioPharm Related Equities
| VCNX | Vaccinex | 5.28 | ||||
| DNTH | Dianthus Therapeutics | 2.27 | ||||
| VCEL | Vericel Corp | 2.13 | ||||
| VCYT | Veracyte | 0.51 | ||||
| VALN | Valneva SE | 0.24 | ||||
| DOMH | Dominari Holdings | 1.19 | ||||
| DNLI | Denali Therapeutics | 1.88 | ||||
| DMAC | DiaMedica Therapeutics | 3.19 | ||||
| VANI | Vivani Medical | 3.76 | ||||
| EQ | Equillium | 4.11 |
Additional Tools for TCBPW Stock Analysis
When running TC BioPharm's price analysis, check to measure TC BioPharm's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy TC BioPharm is operating at the current time. Most of TC BioPharm's value examination focuses on studying past and present price action to predict the probability of TC BioPharm's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move TC BioPharm's price. Additionally, you may evaluate how the addition of TC BioPharm to your portfolios can decrease your overall portfolio volatility.